| Value | ₹5.25 Cr |
|---|
BSE filing, NSE: GODAVARI. Summary written from the filing by ALFA Finder's alert engine.
Godavari Drugs Ltd: key numbers
- Share price
- ₹119.10
- Market cap
- ₹120.6 Cr
- Revenue (annual)
- ₹105.8 Cr
- Net profit (annual)
- ₹4.09 Cr
- P/E (TTM)
- 29.0×Sector 37.9×
- Promoter holding
- 44.54%+4.31% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Godavari Drugs Ltd
All →Godavari Drugs Other Announcement
Godavari Drugs filed its quarterly shareholding pattern for the period ended 30 September 2026. The filing is a routine Regulation 31 disclosure with no transaction.
Godavari Drugs Other Announcement
Godavari Drugs Limited changed its Corporate Identification Number (CIN) following an alteration to its Memorandum of Association's Object Clause. The Ministry of Corporate Affairs registered the change on October 16, 2026.
Godavari Drugs Debt & Borrowing: ₹34 Cr
Godavari Drugs Limited's board approved availing working capital limits of Rs. 34 Crore from ICICI Bank. The facility is within existing shareholder-approved borrowing limits.
- Value
- ₹34.00 Cr
Godavari Drugs Annual General Meeting
Godavari Drugs held its 38th Annual General Meeting on September 25, 2026, via video conferencing. Shareholders approved financial statements, director re-appointment, and object clause alteration.
Godavari Drugs Annual General Meeting
Godavari Drugs Limited will close its register of members and share transfer books from September 19 to September 25, 2026, for its 38th Annual General Meeting.
Godavari Drugs Board Meeting Outcome
Godavari Drugs approved altering its Memorandum of Association to add a nutraceuticals business object. A revised notice for the 38th AGM was also approved.
Other convertible warrants announcements
All →Flywings Simulator Training Centre Convertible Warrants
Flywings seeks approval to issue up to 29.88 lakh warrants at Rs.245, aggregating Rs.73.20 Crore. Includes promoter Rupal Mandavia; EGM is on 27 November 2026.
- Value
- ₹73.20 Cr
- Execution
- Warrants exercisable within 18 months from the date of allotment
Sahana System Convertible Warrants
Sahana System has issued a corrigendum to its postal ballot notice on warrant issuance. Warrants total ₹125 Crore at ₹950 each to identified allottees.
- Value
- ₹125.0 Cr
- Execution
- Warrant conversion within eighteen (18) months
Dev Labtech Venture Convertible Warrants
Dev Labtech Venture approved issuance of up to 1.37 crore convertible warrants at Rs.13 each to promoters and non-promoters on preferential basis. The issue aggregates Rs.17.81 Crore for cash.
- Value
- ₹17.81 Cr
Bajaj Finance Convertible Warrants
Bajaj Finance's special committee meets on 10 November 2026 to approve the price for warrants issued to the promoter. This is a pricing step of a promoter warrant issue.
Dev Labtech Venture Convertible Warrants
Dev Labtech Venture's EGM passed an authorised capital increase and a convertible warrant issue, both with 100% votes in favour. Promoters did not vote on the warrants.
Aequs Convertible Warrants
Aequs Limited allotted 28,071,690 preferential warrants to promoter-trust Mellwood Trustee Services at Rs 231.55 each. The allotment aggregates Rs 650 Crore, with 50% paid upfront.
- Value
- ₹650.0 Cr